Todd Longsworth - Mar 3, 2022 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role: General Counsel
Signature: By: /s/ Steven Robbins, Attorney in Fact for Todd Longsworth
Stock symbol: NVCR
Transactions as of: Mar 3, 2022
Transactions value $: $271,669
Form type: 4
Date filed: 3/7/2022, 05:28 PM
Previous filing: Jul 8, 2021
Next filing: Mar 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCR	Ordinary Shares	Sale	-$81.5K	-1.09K	-1.61%	$74.50	66.8K	Mar 3, 2022	Direct	F1
transaction	NVCR	Ordinary Shares	Sale	-$139K	-1.97K	-2.95%	$70.41	64.8K	Mar 4, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVCR	Options to Buy Ordinary Shares	Award	$492K	+6.11K		$80.59	6.11K	Mar 3, 2022	Ordinary Shares	6.11K	$80.59	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2	Options to buy 6,106 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.

Content

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Options to buy 6,106 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.